PFM Health Sciences, LP holds a diversified book of 96 stocks worth $1.2B as of Q2 2026 (disclosed Aug 14, 2026, a ~45-day 13F lag). This quarter they opened Ascendis Pharma A/s and trimmed Axsome Therapeutics Inc. Their largest long position is Ascendis Pharma A/s at 5% of the equity book. They also disclosed $5.7M in put options (a bearish bet) and $8.0M in call options (bullish), shown separately below and excluded from the equity book.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as PFM Health Sciences, LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Patient Square Capital LP | 10 / 80 | $483.2M |
| Avoro Capital Advisors LLC | 11 / 80 | $7.9B |
| Avidity Partners Management LP | 15 / 80 | $324.0M |
| First Turn Management, LLC | 15 / 80 | $573.0M |
| Boxer Capital Management, LLC | 10 / 80 | $430.4M |
| Integral Health Asset Management, LLC | 33 / 80 | $1.4B |
| Eagle Health Investments LP | 11 / 80 | $317.9M |
| Atle Fund Management AB | 17 / 80 | $195.1M |
Ranked by the share of each fund's own book sitting in the names it shares with PFM Health Sciences, LP: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Ascendis Pharma A/s ORD SHS | $62.2M | 233.2K | 5.4% | ▲New New position | |
| 2 | Axsome Therapeutics Inc. COM | $53.8M | 219.6K | 4.7% | ▼−17% Reduced · −45K sh | |
| 3 | Eli Lilly & Co COM | $47.1M | 39.3K | 4.1% | ▼−40% Reduced · −27K sh | |
| 4 | Jazz Pharmaceuticals PLC SHS USD | $38.7M | 160.8K | 3.4% | ▼−9.8% Reduced · −17K sh | |
| 5 | Humana Inc COM | $37.5M | 94.4K | 3.3% | ▲New New position | |
| 6 | Unitedhealth Group Inc COM | $36.7M | 88.3K | 3.2% | ▲+52% Added · +30K sh | |
| 7 | Neurocrine Biosciences Inc COM | $36.0M | 213.4K | 3.1% | ▼−1.1% Reduced · −2K sh | |
| 8 | Inhibrx Biosciences Inc COM | $29.2M | 308.4K | 2.5% | ▲+1.0% Added · +3K sh | |
| 9 | United Therapeutics Corp Del COM | $27.1M | 50.0K | 2.4% | ▲+26% Added · +10K sh | |
| 10 | Revolution Medicines Inc COM | $26.8M | 143.2K | 2.3% | ▲+1.7% Added · +2K sh | |
| 11 | Icon Pub Ltd Co SHS | $23.7M | 136.5K | 2.1% | ▲+137% Added · +79K sh | |
| 12 | Tenet Healthcare Corp COM NEW | $23.7M | 126.6K | 2.1% | ▼−68% Reduced · −272K sh | |
| 13 | Edwards Lifesciences Corp COM | $22.7M | 250.5K | 2.0% | ▼−1.6% Reduced · −4K sh | |
| 14 | Waters Corp COM | $22.4M | 59.8K | 1.9% | ▲+50% Added · +20K sh | |
| 15 | Penumbra Inc COM | $19.0M | 60.2K | 1.7% | ▼−57% Reduced · −80K sh | |
| 16 | Bridgebio Pharma Inc COM | $18.9M | 253.4K | 1.6% | ▼−1.7% Reduced · −4K sh | |
| 17 | Stryker Corporation COM | $17.8M | 56.6K | 1.5% | ▲+158% Added · +35K sh | |
| 18 | Mettler Toledo International COM | $17.0M | 13.3K | 1.5% | ▲New New position | |
| 19 | Indivior Pharmaceuticals Inc COM | $16.5M | 401.2K | 1.4% | ▼−30% Reduced · −173K sh | |
| 20 | Merck & Co Inc COM | $16.3M | 127.1K | 1.4% | ▲New New position | |
| 21 | Cytokinetics Inc COM NEW | $16.3M | 191.7K | 1.4% | ▲New New position | |
| 22 | Lantheus Hldgs Inc COM | $16.2M | 146.4K | 1.4% | ▲New New position | |
| 23 | Centene Corp Del COM | $16.0M | 248.9K | 1.4% | ▼−5.5% Reduced · −15K sh | |
| 24 | Cooper Cos Inc COM | $15.8M | 220.9K | 1.4% | ▲+30% Added · +51K sh | |
| 25 | Madrigal Pharmaceuticals Inc COM | $15.7M | 29.3K | 1.4% | ▼−14% Reduced · −5K sh | |
| 26 | Acadia Healthcare Company In COM | $15.5M | 524.9K | 1.3% | ▼−9.9% Reduced · −58K sh | |
| 27 | Oruka Therapeutics Inc COM | $15.1M | 158.8K | 1.3% | ▼−8.7% Reduced · −15K sh | |
| 28 | Oscar Health Inc CL A | $14.8M | 519.0K | 1.3% | ▲+3.8% Added · +19K sh | |
| 29 | Thermo Fisher Scientific Inc COM | $14.3M | 28.5K | 1.2% | ▲+92% Added · +14K sh | |
| 30 | CVS Health Corp COM | $14.2M | 137.5K | 1.2% | ▲New New position | |
| 31 | Merit Med Sys Inc COM | $13.7M | 197.0K | 1.2% | ▲+21% Added · +35K sh | |
| 32 | Praxis Precision Medicines I COM NEW | $12.9M | 38.6K | 1.1% | ▲+8.8% Added · +3K sh | |
| 33 | Celldex Therapeutics Inc New COM NEW | $12.8M | 342.8K | 1.1% | ▲+5.5% Added · +18K sh | |
| 34 | Novo-Nordisk A S ADR | $12.7M | 265.0K | 1.1% | ▲+34% Added · +68K sh | |
| 35 | Integer Hldgs Corp COM | $11.8M | 126.7K | 1.0% | ▼−6.2% Reduced · −8K sh | |
| 36 | Dianthus Therapeutics Inc COM | $11.8M | 121.2K | 1.0% | ▼−30% Reduced · −51K sh | |
| 37 | Definium Therapeutics Inc COM SHS | $11.7M | 249.0K | 1.0% | ▲+21% Added · +44K sh | |
| 38 | Gilead Sciences Inc COM | $11.5M | 90.9K | 1.0% | ▲New New position | |
| 39 | Rhythm Pharmaceuticals Inc COM | $11.3M | 101.5K | 1.0% | ▼−26% Reduced · −35K sh | |
| 40 | Schein Henry Inc COM | $11.2M | 134.4K | 1.0% | ▼−12% Reduced · −19K sh | |
| 41 | Arrowhead Pharmaceuticals In COM | $10.7M | 131.7K | 0.9% | ▲+105% Added · +67K sh | |
| 42 | Tango Therapeutics Inc COM | $10.2M | 326.0K | 0.9% | ▼−20% Reduced · −80K sh | |
| 43 | Teleflex Incorporated COM | $10.1M | 79.7K | 0.9% | ▲New New position | |
| 44 | Viking Therapeutics Inc COM | $10.0M | 255.3K | 0.9% | ▼−3.0% Reduced · −8K sh | |
| 45 | Brightspring Health Svcs Inc COM | $9.9M | 141.9K | 0.9% | ▼−24% Reduced · −45K sh | |
| 46 | Vera Therapeutics Inc CL A | $9.6M | 224.3K | 0.8% | ▲+28% Added · +49K sh | |
| 47 | Roivant Sciences Ltd SHS | $9.5M | 268.0K | 0.8% | ▲+29% Added · +61K sh | |
| 48 | CG Oncology Inc COM | $9.1M | 128.3K | 0.8% | ▼−23% Reduced · −38K sh | |
| 49 | Amneal Pharmaceuticals Inc COM STK CL A | $8.3M | 480.7K | 0.7% | ▼−48% Reduced · −449K sh | |
| 50 | Eupraxia Pharmaceuticals Inc COM | $8.0M | 1.21M | 0.7% | ▲+124% Added · +670K sh |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1442756/holdings"
Use Arkolith to show PFM Health Sciences, LP's latest holdings, largest changes, and filing provenance.
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | CENCORA INCCOR | $8.0M | 28K |
| PUT · bearish | CENTENE CORPCNC | $5.7M | 88K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.